Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
OSPEMIFENE vs CLOMID
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.
Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.
Treatment of moderate to severe dyspareunia (painful intercourse) due to vulvar and vaginal atrophy associated with menopause
Treatment of ovulatory dysfunction in women desiring pregnancy (FDA approved),Off-label: treatment of male infertility (oligospermia)
60 mg orally once daily.
50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.
Terminal elimination half-life is approximately 26 hours (range 20–30 hours), supporting once-daily dosing.
Terminal half-life is 5–7 days for zuclomiphene (active isomer), with prolonged elimination due to enterohepatic recirculation.
Primarily metabolized via CYP3A4 and CYP2C9, with minor contributions from CYP2C19, CYP2C8, and CYP2B6. Undergoes glucuronidation and sulfation.
Hepatic via CYP3A4 and CYP2D6; undergoes enterohepatic circulation; terminal half-life ~5-7 days
Primarily hepatic metabolism with biliary excretion; < 30% renal elimination as metabolites. Fecal excretion accounts for approximately 70% of total clearance.
Primarily hepatic metabolism; metabolites excreted in feces (42%) and urine (8% unchanged).
> 99% bound to serum proteins, primarily albumin.
Highly protein bound (>99%), primarily to albumin.
Approximately 4.2 L/kg, indicating extensive tissue distribution.
Not well-characterized; limited data suggest a large Vd (>100 L) due to extensive tissue distribution.
Oral bioavailability is approximately 20–30% due to first-pass metabolism.
Oral bioavailability is approximately 50% due to first-pass metabolism.
No dose adjustment required for mild to moderate renal impairment (Cr Cl ≥15 m L/min). Not studied in severe renal impairment (Cr Cl <15 m L/min) or dialysis.
No specific adjustment required; use caution in severe impairment (Cr Cl <30 m L/min) as data limited.
Contraindicated in Child-Pugh Class C (severe hepatic impairment). No dose adjustment for Child-Pugh Class A or B; use with caution.
Contraindicated in severe hepatic impairment (Child-Pugh class C). For mild to moderate impairment, no adjustment recommended, but monitor liver function.
Not indicated for pediatric use; safety and efficacy not established.
Not indicated for use in children; safety and efficacy not established.
No specific dose adjustment required; pharmacokinetics similar to younger adults. Monitor for vulvovaginal atrophy and thromboembolic risks.
Not indicated for postmenopausal women. Use not recommended in elderly due to lack of efficacy in anovulation.
There is an increased risk of endometrial cancer in women with an intact uterus. Use only when necessary and consider periodic endometrial evaluation.
None
Endometrial cancer risk,Cardiovascular and cerebrovascular events (not evaluated in long-term studies),Venous thromboembolism (potential risk),Breast cancer (long-term safety not established),Use with caution in patients with hepatic impairment
Ovarian hyperstimulation syndrome (OHSS),Ovarian enlargement,Visual disturbances (especially with prolonged use),Multiple pregnancy (increased risk),Ectopic pregnancy,Ovarian cancer risk (theoretical, based on prolonged use)
Undiagnosed abnormal genital bleeding,Known or suspected estrogen-sensitive cancer (e.g., breast cancer),Active or history of venous thromboembolism (e.g., deep vein thrombosis, pulmonary embolism),Pregnancy or women who may become pregnant
Pregnancy (Category X),Liver disease or dysfunction,Undiagnosed abnormal vaginal bleeding,Ovarian cyst or enlargement not due to polycystic ovary syndrome,Hypersensitivity to clomiphene or components
Take with food to minimize GI side effects. No specific food restrictions; however, avoid grapefruit juice as it may increase drug levels via CYP3A4 inhibition.
No specific food interactions. Avoid grapefruit as it may alter metabolism (theoretical due to CYP3A4 involvement).
Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There are no adequate human data; however, based on its estrogenic and antiestrogenic activity, it may interfere with fetal development. Use is not recommended at any trimester.
Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs during the first trimester. Second and third trimester risks are not well studied due to contraindication, but theoretical risks include ovarian hyperstimulation syndrome (OHSS) effects on pregnancy.
It is unknown whether ospemifene is excreted in human breast milk. No M/P ratio is available. Due to potential serious adverse effects in the nursing infant, breastfeeding is not recommended during treatment and for one week after the last dose.
Safety in breastfeeding is not established. Clomiphene may reduce milk production. The M/P ratio is unknown. It is generally not recommended during breastfeeding.
Ospemifene is contraindicated in pregnancy; therefore, no dosing adjustments are recommended. If pregnancy occurs, therapy should be discontinued. Due to lack of data and potential harm, no alternative dosing during pregnancy is advised.
No dose adjustments are relevant as clomiphene is contraindicated in pregnancy. Pharmacokinetic changes in pregnancy are not applicable due to contraindication.
Ospemifene is a selective estrogen receptor modulator (SERM) indicated for moderate to severe dyspareunia due to vulvar and vaginal atrophy (VVA) in postmenopausal women. It has estrogenic effects on vaginal tissue but antiestrogenic effects on breast and endometrium. Monitor for thromboembolic events; contraindicated in history of VTE or PE. Not for use in women with breast cancer or estrogen-dependent neoplasia. May cause hot flashes and vaginal discharge.
Monitor ovarian size via ultrasound to reduce risk of ovarian hyperstimulation syndrome (OHSS). Limit course to 3-6 cycles due to increased risk of ovarian tumors. Check pregnancy test before each cycle. Use with caution in liver disease.
Take one 60 mg tablet daily with food to reduce gastrointestinal upset.,Notify your healthcare provider if you experience unusual vaginal bleeding, breast pain, or lumps.,Seek immediate medical attention for signs of blood clots: chest pain, shortness of breath, leg swelling or pain, sudden severe headache.,Do not use if you have a history of blood clots, breast cancer, or liver disease.,Ospemifene is for non-surgical women postmenopausal; it does not prevent pregnancy or sexually transmitted infections.,Avoid smoking and limit alcohol intake to reduce the risk of blood clots.
Take exactly as prescribed, typically 50 mg daily for 5 days starting on day 5 of menstrual cycle.,Report abdominal pain, bloating, nausea, or weight gain (possible OHSS).,Avoid alcohol due to hepatotoxicity risk.,Most pregnancies occur within first 3 cycles; consider alternative after 6 cycles.,May cause visual disturbances; report blurred vision or spots.
"Ospemifene, a selective estrogen receptor modulator, inhibits the metabolism of thiotepa, an alkylating agent, by competitively inhibiting cytochrome P450 (CYP) 2B6 and potentially other CYP enzymes involved in thiotepa's biotransformation. This leads to increased systemic exposure to thiotepa, elevating the risk of dose-dependent toxicities such as severe myelosuppression (e.g., neutropenia, thrombocytopenia) and mucositis. Clinically, coadministration may require significant thiotepa dose reduction to avoid excessive bone marrow suppression."
"Ospemifene is primarily metabolized by CYP3A4, and thioridazine is a moderate inhibitor of CYP3A4. Coadministration reduces ospemifene clearance, leading to elevated ospemifene serum concentrations, which may increase the risk of dose-dependent adverse effects such as thromboembolic events, hot flashes, and vaginal discharge. This interaction is clinically significant as it may exacerbate the endocrine and cardiovascular side effects of ospemifene."
"Ospemifene, a selective estrogen receptor modulator (SERM), is primarily metabolized by the cytochrome P450 enzyme CYP3A4. Clarithromycin is a potent macrolide antibiotic and a strong inhibitor of CYP3A4. Coadministration of clarithromycin with ospemifene significantly reduces the metabolic clearance of clarithromycin, leading to increased plasma concentrations of clarithromycin. This elevation can potentiate clarithromycin's adverse effects, including QT interval prolongation, cardiac arrhythmias, hepatotoxicity, and gastrointestinal disturbances, particularly in patients with preexisting risk factors."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about OSPEMIFENE vs CLOMID, answered by our medical review team.
OSPEMIFENE is a Selective Estrogen Receptor Modulator (SERM) that works by Ospemifene is a selective estrogen receptor modulator (SERM) that acts as an agonist on estrogen receptors in vaginal tissues, leading to proliferation and maturation of vaginal epithelium, while exhibiting antagonist activity on breast and endometrial tissues.. CLOMID is a Selective Estrogen Receptor Modulator that works by Competitive antagonist of estrogen receptors (ER) in hypothalamus and pituitary, leading to increased gonadotropin-releasing hormone (Gn RH) and subsequent LH and FSH release, stimulating ovulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between OSPEMIFENE and CLOMID depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of OSPEMIFENE is: 60 mg orally once daily.. The standard adult dose of CLOMID is: 50 mg orally once daily for 5 days, starting on day 5 of the menstrual cycle. May increase to 100 mg daily if no response.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between OSPEMIFENE and CLOMID in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. OSPEMIFENE is classified as Category C. Ospemifene is contraindicated in pregnancy due to potential fetal harm. In animal studies, it caused fetal malformations (e.g., skeletal abnormalities) and embryo-fetal loss. There. CLOMID is classified as Category C. Clomiphene citrate is contraindicated in pregnancy. It is associated with an increased risk of fetal malformations, including neural tube defects, specifically when exposure occurs. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.